De behandeling van hersenmetastasen

J. M. M. Gijtenbeek; A. T. C. J. van Eck; R. W. M. van der Maazen; A. C. Koetsveld; C. J. A. Punt

De behandeling van hersenmetastasen

J. M. M. Gijtenbeek, A. T. C. J. van Eck, R. W. M. van der Maazen, A. C. Koetsveld, C. J. A. Punt

Other Departments

Research output: Contribution to journal › Article › Professional

2 Citations (Scopus)

Abstract

Patients with cancer have a 15 to 30% risk of developing symptomatic brain metastases. The prognosis is extremely poor then: the median survival period is less than one year. Treatment strategies aim to guarantee an optimal quality of life. Curative treatment can only be given in just a few unique cases. Besides the previous standard treatment of whole-brain radiotherapy, the efficacy of other treatment modalities as surgery, radiosurgery, and systemic chemotherapy has been demonstrated to have additional value for certain indications. Important factors that play a role in the decision to give a specific treatment are the age and performance status of the patient, the number of brain metastases and their location, the systemic tumour activity, and the radiosensitivity and chemosensitivity of the primary tumour. A multidisciplinary approach is necessary to guarantee an optimal treatment plan

Original language	Dutch
Pages (from-to)	1724-1729
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	146
Issue number	37
Publication status	Published - 2002

Cite this

@article{a18ce1a67ade43e0b37c8856f7158c80,

title = "De behandeling van hersenmetastasen",

abstract = "Patients with cancer have a 15 to 30% risk of developing symptomatic brain metastases. The prognosis is extremely poor then: the median survival period is less than one year. Treatment strategies aim to guarantee an optimal quality of life. Curative treatment can only be given in just a few unique cases. Besides the previous standard treatment of whole-brain radiotherapy, the efficacy of other treatment modalities as surgery, radiosurgery, and systemic chemotherapy has been demonstrated to have additional value for certain indications. Important factors that play a role in the decision to give a specific treatment are the age and performance status of the patient, the number of brain metastases and their location, the systemic tumour activity, and the radiosensitivity and chemosensitivity of the primary tumour. A multidisciplinary approach is necessary to guarantee an optimal treatment plan",

author = "Gijtenbeek, {J. M. M.} and {van Eck}, {A. T. C. J.} and {van der Maazen}, {R. W. M.} and Koetsveld, {A. C.} and Punt, {C. J. A.}",

year = "2002",

language = "Dutch",

volume = "146",

pages = "1724--1729",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

number = "37",

}

TY - JOUR

T1 - De behandeling van hersenmetastasen

AU - Gijtenbeek, J. M. M.

AU - van Eck, A. T. C. J.

AU - van der Maazen, R. W. M.

AU - Koetsveld, A. C.

AU - Punt, C. J. A.

PY - 2002

Y1 - 2002

N2 - Patients with cancer have a 15 to 30% risk of developing symptomatic brain metastases. The prognosis is extremely poor then: the median survival period is less than one year. Treatment strategies aim to guarantee an optimal quality of life. Curative treatment can only be given in just a few unique cases. Besides the previous standard treatment of whole-brain radiotherapy, the efficacy of other treatment modalities as surgery, radiosurgery, and systemic chemotherapy has been demonstrated to have additional value for certain indications. Important factors that play a role in the decision to give a specific treatment are the age and performance status of the patient, the number of brain metastases and their location, the systemic tumour activity, and the radiosensitivity and chemosensitivity of the primary tumour. A multidisciplinary approach is necessary to guarantee an optimal treatment plan

AB - Patients with cancer have a 15 to 30% risk of developing symptomatic brain metastases. The prognosis is extremely poor then: the median survival period is less than one year. Treatment strategies aim to guarantee an optimal quality of life. Curative treatment can only be given in just a few unique cases. Besides the previous standard treatment of whole-brain radiotherapy, the efficacy of other treatment modalities as surgery, radiosurgery, and systemic chemotherapy has been demonstrated to have additional value for certain indications. Important factors that play a role in the decision to give a specific treatment are the age and performance status of the patient, the number of brain metastases and their location, the systemic tumour activity, and the radiosensitivity and chemosensitivity of the primary tumour. A multidisciplinary approach is necessary to guarantee an optimal treatment plan

M3 - Article

C2 - 12357872

SN - 0028-2162

VL - 146

SP - 1724

EP - 1729

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

IS - 37

ER -